Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT1H9Z)

Drug Name

KOTALANOL Drug Info

Synonyms

Kotalanol; 214491-07-3; CHEMBL1093264; (1S,2R,3R,4S)-1-{(1S)-2-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrothiophenium-1-yl]-1-hydroxyethyl}-2,3,4,5-tetrahydroxypentyl sulfate; CHEMBL1233894; DTXSID10655282; BDBM50316179; FT-0670687; 1,4-Dideoxy-1,4-[(S)-[7-deoxy-5-O-sulfo-D-glycero-D-galacto-heptitol-7-yl]episulfoniumylidene]-D-arabinitol Inner Salt; 1,4-Dideoxy-1,4-[[2S,3S,4R,5R,6S-2,4,5,6,7-pentahydroxy-3-(sulfooxy)heptyl]-(R-)epi-sulfoniumylidine]-D-arabinitol

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 42632210
CAS Number: CAS 214491-07-3
TTD Drug ID: DMT1H9Z

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Intestinal maltase-glucoamylase (MGAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voglibose	DMUBP9O	Diabetic complication	5A2Y	Approved	[2]
Acarbose	DMRM3AW	Diabetic complication	5A2Y	Approved	[3]
Miglitol	DMXBQAM	Diabetic complication	5A2Y	Approved	[4]
Rh-alphaglucosidase	DMNF0G8	Pompe disease	5C51.3	Approved	[5]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[6]
Alpha-glucosidase	DM2RTGP	Muscle disease	FB3Z	Phase 3	[7]
PAZ-320	DMU0812	Type-2 diabetes	5A11	Phase 2	[8]
SC-49483	DM180VX	Acquired immune deficiency syndrome	1C62.3	Phase 2	[9]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[10]
SALACINOL	DMVKQT8	N. A.	N. A.	Phase 1/2	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Intestinal maltase-glucoamylase (MGAM)	TTXWASR	MGA_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
2	Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
5	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
6	Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
8	Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.
9	Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8.
10	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.